文献速递中枢神经肿瘤放疗

新诊断胶质母细胞瘤的新型递归 partitioning 分析分类:强调 MGMT 启动子甲基化和 IDH1 基因突变状态的多中心研究

Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.
PubMed 文献 · Radiother Oncol · 2017-03-13

BACKGROUND AND PURPOSE: To refine the recursive partitioning analysis (RPA) classification for glioblastoma incorporating the MGMT methylation and IDH1 mutation status.…

要点

  • MGMT 甲基化是 RPA 初始分层的首要因素。
  • 三个 RPA 类别的中位生存分别为 67.2、24.0 和 15.2 个月。
  • 该模型可用于未来临床试验的患者分层。

核心结论

  • 在替莫唑胺时代,整合 MGMT 甲基化和 IDH1 突变状态的新型 RPA 分类能有效区分胶质母细胞瘤患者的预后。

主要发现

  • MGMT 甲基化和 IDH1 突变分别见于 42.4% 和 6.2% 的患者。
  • 生存者中位随访 33.2 个月,所有患者中位随访 20.5 个月,中位生存 23.6 个月。
  • RPA 识别出三个最终类别:I 类中位生存 67.2 个月,II 类 24.0 个月,III 类 15.2 个月。

关键数值与推荐

  • I 类定义:MGMT 甲基化/IDH1 突变,或 MGMT 甲基化/IDH1 野生型/全切除/KPS≥90。
  • II 类定义:MGMT 甲基化/IDH1 野生型/全切除/KPS<90,或 MGMT 甲基化/IDH1 野生型/残留病灶,或 MGMT 未甲基化/年龄<50 岁,或 MGMT 未甲基化/年龄≥50 岁/全切除。
  • III 类定义:MGMT 未甲基化/年龄≥50 岁/残留病灶。

临床怎么用

  • 该 RPA 模型可用于未来临床试验中基于分子特征的患者分层。

局限性

  • 外部验证正在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To refine the recursive partitioning analysis (RPA) classification for glioblastoma incorporating the MGMT methylation and IDH1 mutation status. METHODS AND MATERIALS: Three-hundred forty patients were treated with radiotherapy plus concurrent and adjuvant temozolomide in three tertiary-referral hospitals. MGMT methylation and IDH1 mutation status were available in all patients. Methylation of the MGMT (MGMTmeth) and mutation of IDH1 (IDH1mut) were observed in 42.4% and 6.2% of the patients, respectively. RESULTS: The median follow-up for survivors and all patients was 33.2 and 20.5months, respectively. The median survival (MS) was 23.6months. RPA was performed on behalf of the results of the Cox proportional hazards model. MGMT methylation generated the initial partition (MGMTmeth vs. MGMTunmeth) in the RPA. Three final RPA classes were identified; class I=MGMTmeth/IDH1mut or MGMTmeth/IDH1wt/GTR/KPS≥90 (MS, 67.2months); class II=MGMTmeth/IDH1wt/GTR/KPS<90, MGMTmeth/IDH1wt/residual disease, MGMTunmeth/age<50, or MGMTunmeth/age≥50/GTR (MS, 24.0months); class III=MGMTunmeth/age≥50/residual disease (MS, 15.2months). CONCLUSIONS: A novel RPA classification for glioblastoma was formulated highlighting the impact of MGMTmeth and IDH1mut in the temozolomide era. This model integrating pertinent molecular information can be used effectively for the patient stratification in future clinical trials. An external validation is ongoing.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Wee CW, Kim E, Kim N, et al. Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. Radiother Oncol. 2017. PMID: 28302331. doi:10.1016/j.radonc.2017.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。